Multiple myeloma is characterized by the proliferation of clonal plasma cells that have a heterogeneous expression of various cell surface markers, precluding successful use of monoclonal antibodies for therapeutic targeting of the tumor cell. Thymoglobulin (rabbit-derived polyclonal anti-thymocyte globulin), by virtue of its method of preparation, contains antibodies against several B-cell and plasma cell antigens and offers an attractive option for immunotherapy of myeloma. Here, we demonstrate potent anti-myeloma activity of the rabbit anti-thymocyte globulin preparation Thymoglobulin in vitro and in vivo in an animal model of myeloma. Thymoglobulin was able to induce dose-and time-dependent apoptosis of several myeloma cell lines, including those resistant to conventional anti-myeloma agents. Importantly, the anti-myeloma activity was preserved even when myeloma cells were grown with different cytokines demonstrating the ability to overcome microenvironmentmediated resistance. Thymoglobulin induced apoptosis of freshly isolated primary myeloma cells from patients. Using a competitive flow cytometric analysis, we were able to identify the potential antigen targets for Thymoglobulin preparation. Finally, in a plasmacytoma mouse model of myeloma, Thymoglobulin delayed the tumor growth in a dose-dependent manner providing convincing evidence for continued evaluation of this agent in the clinic in patients with myeloma, either alone or in combination with other agents.
Introduction
Multiple myeloma (MM) is a plasma cell malignancy that affects over 16 000 individuals in United States each year and results in over 12 000 related deaths during the same period. The median survival for the individuals affected by myeloma has been estimated to be 3-5 years from initiation of therapy. Although new therapies have improved the response rates and possibly the overall survival of these patients, it remains incurable with the current approaches. High-dose therapy and stem cell transplantation, while improving survival compared to combination chemotherapy still fails to cure the disease or provide lasting remissions. Better understanding of the disease biology over the past several years is starting to translate into more effective therapies. Novel approaches, particularly combinations of active agents, are urgently needed to attack this disease and improve the outcome of patients with myeloma.
Targeting cell surface antigens using monoclonal antibodies represents a very attractive approach for treatment of malignancies that has been borne out by the success of Rituximab in patients with non-Hodgkin's lymphoma. Monoclonal antibodies, especially humanized antibodies, are usually very well tolerated with very minimal side effects as has been the experience with Rituximab. The ability to target tumor cells with minimal bystander effect is of particular advantage with this approach. Unfortunately, myeloma cells represent a heterogeneous population in terms of the expression of various cell surface antigens. Myeloma cells express various surface antigens, including CD38, CD138, CD45, adhesion molecules such as VLA4, and other lymphocyte antigens such as CD52 depending on the stage of maturation with considerable variation from patient to patient. This heterogeneity makes use of monoclonal antibodies in the treatment of myeloma, particularly challenging, as has been demonstrated by the lack of benefit for therapies targeting any one of these antigens. This calls for the use of antibody preparations that can target multiple antigens at the same time, possibly a polyclonal preparation.
Rabbit-derived anti-thymocyte globulin (rATG, Thymoglobulin; Genzyme/Sangstat) is prepared by immunizing rabbits with cells derived from fragments of thymus glands. Thymoglobulin has been used extensively in the setting of solid organ transplantation as well as in the hematopoietic stem cell transplant for immunosuppression. Additionally, it has also been used for the treatment of refractory graft-versus-host disease following allogeneic stem cell transplants. Unlike the earlier monoclonal preparations directed against specific T-cell antigens, Thymoglobulin is a polyclonal preparation containing antibodies to a variety of T-and B-cell antigens. Studies have shown that the thymus, in addition to the thymocytes which usually express the T-cell antigens, also have 5-10% plasma cells. This results in a preparation that also contains antibodies against plasma cell/B-cell antigens. This was first noticed when patients undergoing solid organ transplants receiving Thymoglobulin had a significantly decreased risk of Epstein-Barr virus (EBV)-related lymphoproliferative disorder, which was determined to be related to the presence of antibodies in the preparation directed against the B-cell antigens, leading to their destruction. Also noted in the renal transplant recipients was the depletion of plasma cells and a decrease in the immunoglobulin levels. Previous studies using the polyclonal thymocyte preparations had demonstrated their ability to deplete B cells as well. Given this scenario, Thymoglobulin has been evaluated in vitro in the setting of myeloma.
Materials and methods

MM cell lines
Dexamethasone sensitive (MM1.S) and resistant (MM1.R) human MM cell lines were obtained from Dr Steven Rosen (Northwestern University, Chicago, IL, USA). Doxorubicin resistant (Dox 40)-, mitoxantrone resistant (MR20)-and melphalan resistant (LR5)-Rosewell Park Memorial Institute medium (RPMI) 8226 human MM cells and sensitive RPMI 8226 cell lines were obtained from Dr William Dalton (Moffitt Cancer Center, Tampa, FL, USA). OPM1 and OPM2 cell lines were obtained from Dr Lief Bergsagel (Mayo Clinic, AZ, USA) and the U266 cell line was obtained from American Type Culture Collection (Rockville, MD, USA). All cell lines were cultured in RPMI 1640 media (Sigma Chemical, St Louis, MO, USA) that contained 10% fetal bovine serum (FBS), 2 mmol/l L-glutamine (GIBCO, Grand Island, NY, USA), 100 U/ml penicillin and 100 mg/ml streptomycin.
Thymoglobulin
Thymoglobulin was supplied by Genzyme Corporation (Cambridge, MA, USA) as a sterile, non-pyrogenic, freeze-dried powder to be reconstituted with sterile water for injection, USP, for intravenous administration. Each product package contains two 7 ml vials: vial 1 containing freeze-dried Thymoglobulin (contains 25 mg anti-thymocyte rabbit immunoglobulin, glycine, mannitol and sodium chloride), and vial 2 containing sterile water for injection, USP (5 ml).
The 5 ml of diluent is added slowly to the powder using sterile technique. The vial is gently rotated until all powder is completely dissolved. For animal studies, the required dose was diluted in sterile saline for injection and mixed gently before administration.
Cell proliferation and cytotoxicity assays
Myeloma cells (2-3 Â 10 4 cells/well) were incubated in 96-well culture plates (Costar, Cambridge, MA, USA) in media alone or with Thymoglobulin for 48 h at 371C. To evaluate the effect of growth factors, recombinant interleukin-6 (IL-6) (10 ng/ml), insulin-like growth factor (IGF)-1 (50 ng/ml) or vascular endothelial growth factor (VEGF) (25 ng/ml) were added. The cellular cytotoxicity of Thymoglobulin against myeloma cells was assessed using colorimetric assays with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide (MTT; Chemicon International Inc., Temecula, CA, USA). Cells from 48-h cultures were pulsed with 5 mg/ml MTT (10 ml/well); 96-well plates were incubated at 371C for 4 h, followed by 100 ml isopropanol containing 0.04 N HCl. Absorbance at a wavelength of 570 nm (with correction using readings at 630 nm) were measured on a spectrophotometer (Molecular Devices Corp., Sunnyvale, CA, USA). Background absorbance (obtained from wells containing media alone) was subtracted from the observed data; the mean of triplicate readings was used.
Detection of apoptosis in myeloma cell lines and patient myeloma cells For evaluation of patient myeloma cells, bone marrow aspirates were subjected to ACK lysis and mononuclear cells were separated. Myeloma cells were separated by positive selection using CD138 coated magnetic beads in a Robosep system. The tumor cells were suspended in RPMI 1640 media containing 20% FBS, 2 mmol/l L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin, placed in 24-well plates and Thymoglobulin added at different concentrations. Patient cells were cultured for 48 h, harvested and washed twice with PBS, and stained with FITC-conjugated CD45 monoclonal antibody and 7-AAD for identification of apoptotic cells. The cells were then analyzed using DIVA software on an FACSCanto flow cytometer (BD Biosciences).
Determination of plasma cell targets for Thymoglobulin
MM1.S, OPM2, U266 and RPMI 8226 cells were plated into sixwell plates at a concentration of 10 million cells/well, with or with out Thymoglobulin added at a concentration of 1 mg/ml. After 24 h, the cells were harvested and washed once with PBS. Three tubes were set up with each of the following markers: g1 fitc, g1 pe, cd45 fitc, cd20 fitc, cd27 fitc, cd52 fitc, cd40 fitc, cd38 pe, cd22 pe, cd19 pe, cd138 pe, cd184, cd56, cd49d, cd126, cd154, and anti-rabbit fitc. Into tube 2 was also aliquoted 20 ml of ATG (1:10 of 5000 mg/ml stock). Untreated cells were distributed into tubes 1 (no ATG control series) and 2 (ATG þ labeled reagent competitive series), whereas 24 h ATG-treated cells were added to tube 3. The cells were incubated for 15 min in the dark at room temperature. Two milliliters of PBS was added to each tube and they were centrifuged for 5 min at 300 g. The pellets were resuspended in 0.5 ml of 1% paraformaldehyde and stored in the dark at 41C until run on the BD FACSCanto.
Mouse model
CB17 black severe combined immunodeficient (SCID) mice were obtained from Harlan Laboratories and maintained in a mouse barrier facility. RPMI 8226 cells were grown in RPMI 1640 media with 10% FBS as described previously. RPMI 8226 cells were harvested, washed twice with sterile PBS and re-suspended in sterile PBS at a concentration of 10 million cells per 500 ml. The mice were prepared by removing hair from a 1 cm 2 area of the right flank. The RPMI 8226 cell suspension was injected subcutaneously over the right flank of the mice, each mouse receiving 10 million cells. The animals were closely followed until tumor growth was established. Once the tumors were at least 0.25 cm 2 in size, they were randomized into three groups of 11 mice each. Group A received no treatment, group B mice received Thymoglobulin intraperitoneally (i.p.) at 5 mg/kg and group C received Thymoglobulin 10 mg/kg by the same route. Both groups received five daily injections of Thymoglobulin at these concentrations. The mice were followed regularly and tumors measured every 3 days. The tumor volume was calculated as length Â (breadth) 2 /2 and the mice were killed once the tumor volume reached 2.5 cm 3 . The mean tumor volumes across the three groups were compared and the survival of the mice in the three groups was compared using Kaplan-Meier curves and log rank statistics.
Results
Thymoglobulin is cytotoxic to myeloma cell lines
Thymoglobulin was cytotoxic to several different myeloma cell lines in a dose-and time-dependent manner as measured using MTT colorimetric assay for cell viability (Figure 1 ). Thymoglobulin was cytotoxic to more than 50% of the cells at a concentration of approximately 0.5 mg/ml for most of the cell lines. In addition, we also evaluated the effect of Thymoglobulin on the IL-6-dependent cell line KAS-6/1 and found a similar degree of cytotoxicity following treatment with Thymoglobulin. Most importantly, Thymoglobulin was able to induce cytotoxicity at similar concentrations in cell lines known to be resistant to common anti-myeloma drugs like MM1.R (dexamethasone resistant), Dox 40 (doxorubicin resistant) and LR5 (melphalan resistant) (Figure 1b) . Maximum cytotoxic effect was seen at 72 h of incubation with only slightly lower activity at 48 h of incubation (Figure 1c ).
Thymoglobulin induces apoptosis of myeloma cell lines and primary myeloma cells
We examined the ability of Thymoglobulin to induce apoptosis of myeloma cell lines using flow cytometric evaluation of Annexin/PI staining. Thymoglobulin induced a time-(data not shown) and dose-dependent apoptosis of myeloma cell lines as shown by the increase in the Annexin-positive, PI-negative population of cells (Figure 2a) . The proportion of dead necrotic (Annexin and PI positive) cells also increased with time and dose.
We then treated freshly isolated primary myeloma cells with increasing concentrations of Thymoglobulin. Thymoglobulin induced apoptosis in primary myeloma cells as determined by 7-AAD staining of the cells following incubation with the drug for 36-48 h (Figure 2b ). Several samples were tested and heterogeneity was seen in the sensitivity of primary myeloma cells to Thymoglobulin.
Thymoglobulin overcomes the effect of microenvironment and enhances the activity of conventional chemotherapy agents
We next examined if Thymoglobulin can overcome the resistance observed when myeloma cells are cultured in conditions simulating the tumor microenvironment. When myeloma cells were grown in the presence of IL-6, VEGF or IGF, cytokines known to be important for myeloma cell growth, Thymoglobulin was able to induce comparable cytotoxicity reflecting the ability of the antibody to overcome the resistance afforded by the tumor microenvironment (Figure 3a) .
We examined the effect of combining Thymoglobulin with common anti-myeloma therapies including melphalan, adriamycin, dexamethasone and velcade. When myeloma cells were treated simultaneously with Thymoglobulin and each of these drugs, an additive effect was noted with melphalan ( Figure 3b ) and dexamethasone (not shown) across all the dose ranges.
Thymoglobulin targets multiple cell surface antigens on myeloma cells
We examined the potential antigenic targets for Thymoglobulin on myeloma cells by a competitive flow cytometric method. Four different myeloma cell lines (MM1.S, RPMI 8226, U266 and OPM2) were examined to assess the maximum number of potential antigenic targets. When cells were treated with
Thymoglobulin and compared to untreated cells, a significant decrease in the detection of several B cell and plasma cell antigens was observed, as measured by a gate shift or intensity 
Thymoglobulin slows tumor growth in an animal model of myeloma
Six-week-old SCID mice were injected with RPMI 8226 cells subcutaneously as described in the Methods section. Once tumors were established, mice received no injections (control group), or Thymoglobulin 5 mg/kg i.p. (group B) or Thymoglobulin 10 mg/kg i.p. (group C). When the animals were followed serially, there was a significant difference in the tumor growth between treated mice and the untreated mice, with group C receiving the maximum benefit from the Thymoglobulin (Figure 5a ). Survival analysis using Kaplan-Meier product limit method demonstrated a significantly shorter survival for the untreated animals compared to the treated animals demonstrating a slowing of tumor growth owing to Thymoglobulin treatment.
Discussion
ATG and anti-lymphocyte globulin (ALG) have been used as potent immunosuppressive agents following solid organ transplants for over two decades. In addition, it has been extensively used for the treatment of aplastic anemia and more recently is increasingly becoming a part of reduced-intensity conditioning regimens for allogeneic stem cell transplants. Traditionally, the ATGs have been thought to exert their activity through their ability to target and destroy T-cells. In recent years, attention has been brought to bear on the potent anti-B-cell activity of several of these preparations, especially that of the rabbit-derived polyclonal ATG. Several key clinical observations have led to studies demonstrating the presence of antibodies directed against B-cell antigens. In patients receiving cardiac transplants and the monoclonal antibody OKT3 for immunosuppression, the incidence of lymphoproliferative disorders was higher compared to a control group who received ALG. 1 BonnefoyBerard et al. 2 expanded on this observation and demonstrated that various ALG preparations, irrespective of the source of lymphocytes (thoracic duct lymphocytes, thymocytes or lymphocyte cell lines) used for immunization, contained antibodies directed against various B-cell antigens in addition to the anti-T-cell antibodies. In addition, the authors observed that ALG had an inhibitory effect on various ligands known to induce B-cell differentiation and proliferation including pokeweed mitogen and CD40L. They also observed an inhibitory effect of ALG on several lymphoma cell lines as well as other EBV-transformed cells.
More recently, Shah et al. 3 reported on the efficacy of polyclonal rabbit ATG (Thymoglobulin) in treating antibodymediated renal allograft rejection. This led to additional studies with the Thymoglobulin preparation, which clearly demonstrated its ability to induce apoptosis of naive and activated human B cells and plasma cells. 4 The authors went on to demonstrate the presence of antibodies directed against various B cell and plasma cell antigens in the Thymoglobulin preparation explaining these findings. Studies on pediatric thymi clearly confirm that approximately 6% of the cells are CD138 þ plasma cells and CD20 þ B cells. Thus, the Thymoglobulin preparation offers the potential to target multiple plasma cell antigens using a single preparation and represents an attractive strategy for therapeutic use in plasma cell malignancies.
In this study, we clearly demonstrate the ability of Thymoglobulin to induce cytotoxicity in myeloma cell lines as well as patient-derived myeloma cells. A dose-dependent induction of apoptosis was confirmed by flow cytometry on myeloma cell lines as well as patient-derived myeloma cells. These results confirm previous observations that suggested induction of apoptosis when treated with 0.1-1 mg/ml of Thymoglobulin. 5, 6 Previous studies have implicated various mechanisms for the anti-myeloma activity of Thymoglobulin. A role for complement has been suggested by previous studies that showed enhanced cytotoxicity of Thymoglobulin when cells are incubated in the presence of complement. 4, 6 In addition, Zand et al. 4 demonstrated decreased activity when cells were treated with the F(ab) 2 fragments instead of the whole antibody, an effect that was reversed by Fc ligation using other antibodies. The cytotoxic effects of the Thymoglobulin on myeloma cells are also clearly observed in the absence of complement as in this study. [4] [5] [6] Importance of the caspases has been highlighted in a previous study where the cytotoxicity was significantly reduced in the presence of caspase inhibitors 5 and a second study that demonstrated activation of caspases 3, 8 and 9 in several myeloma cell lines. 6 The current study found that Thymoglobulin was able to induce apoptosis of myeloma cells resistant to conventional anti-myeloma agents, demonstrating non-overlapping mechanisms of action. More importantly, it was able to induce apoptosis of myeloma cells when they were grown in the presence of IL-6, VEGF or IGF, which are important for tumor cell survival and proliferation in the marrow microenvironment.
We then examined the specific antigens on the plasma cells that are being targeted by the Thymoglobulin preparation to further understand the anti-myeloma activity of the polyclonal Thymoglobulin preparation as well as to gauge the clinical utility of this approach. Using a competitive flow cytometry assay, we have identified some of the relevant targets on the myeloma cells. The spectrum of antibodies gives an important insight into the potential impact of using Thymoglobulin as a therapeutic agent for myeloma. Antibodies against syndecan-1 (CD138) and CD38, antigens commonly present on the plasma cell surface, may be responsible for at least some of the antimyeloma activity. Antibodies against the common leukocyte antigen (CD45), IL-6 receptor alpha chain (CD126), VLA4 (Integrin a4, CD49d), and B-cell antigen CD20, also likely play a role in the anti-myeloma activity seen with Thymoglobulin. Syndecan-1 (CD138) is a heparan sulfate bearing proteoglycan found on various epithelial cells as well as on B lineage cells depending on the stage of development. Syndecan-1 (CD138) is abundantly expressed by plasma cells, especially myeloma cells. The extracellular domain along with the heparan sulfate side chains can be cleaved off of the cell surface and can be detected in the serum as soluble syndecan-1. Syndecan-1 has been shown to be an independent prognostic factor in patients with MM and in vitro it can promote myeloma cell growth through different mechanisms. CD138 has been proposed as a therapeutic target for treatment of myeloma.
7 CD38 is a type II transmembrane protein that is uniformly present on the surface of myeloma cells and has been the focus of novel therapeutic approaches for myeloma. [8] [9] [10] In addition, this antigen is also present on thymic T-cells as well as activated lymphocytes. IL-6 is one of the most important cytokines for proliferation and survival of myeloma cells and myeloma cells uniformly express the receptor for IL-6 which consists of an alpha chain (CD126) and a beta chain (CD130). 11, 12 VLA4 is an important adhesion molecule that is present on the myeloma cell surface and is believed to play an important role in adhesion-mediated drug resistance as well as interaction with the stromal cell that is crucial for myeloma cell survival. [13] [14] [15] [16] [17] [18] Targeting VLA4 may be able to enhance the activity of other myeloma drugs and strengthens the rational for combining Thymoglobulin with these therapies.
19 CD20 expression is variable on myeloma cells and anti-CD20 monoclonal antibody-based therapies have limited utility in myeloma. However, some recent data suggest that the early myeloma cells may have higher expression of CD20 and Thymoglobulin may provide a mechanism to target these cells. 20 The expression of various antigens are highly variable in myeloma cells, and by virtue of the polyclonal nature of the product, Thymoglobulin has the ability to target a wide spectrum of myeloma cells both in terms of intra-and interpatient heterogeneity. 21 In conclusion, we demonstrate the in vivo activity of Thymoglobulin in a mouse model of myeloma and provide convincing evidence for clinical evaluation of this preparation in patients with myeloma. The animal studies also point towards a dose response given the difference between the two groups, again suggesting anti-myeloma activity of the preparation. Higher daily doses or longer treatment schedule may have resulted in increased activity, but was not pursued in this study. Given the phenotypic heterogeneity of the myeloma cells and the limitations with regard to the total amount of Thymoglobulin that can be administered secondary to the immunosuppressive effects, we hypothesize that a combination of Thymoglobulin with another effective myeloma agent such as an alkylating agent is likely to have better success than Thymoglobulin alone. The results presented here will form the framework for a proposed clinical trial of Thymoglobulin and melphalan in patients with relapsed myeloma.
